Evidence map›Paper›PMID 35413298›Full record

ArticleClinica chimica acta; international journal of clinical chemistry2022

Molecular diagnostics of SARS-CoV-2: Findings of an international survey.

Aldo Vacaflores Salinas, Tester Ashavaid, Deborah A Payne, Mark W Linder, Katarina Baluchova, Shiyang Pan, Jim Huggett, Parviz Ahmad-Nejad, IFCC Committee for Molecular Diagnostics C-MD

Open access · greenAbstract read
In one paragraph

Article in Clinica chimica acta; international journal of clinical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Aldo Vacaflores SalinasPlexus Laboratorio, La Paz, Bolivia.
Tester AshavaidDepartment of Laboratory Medicine, P.D. Hinduja National Hospital and Medical Research Center, Mumbai, India.
Deborah A PayneCPDP Consulting, LLC, Denver, CO, USA.
Mark W LinderDepartment of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY USA.
Katarina BaluchovaLABCON-OWL Analytics, Research and Consulting GmbH, Bad Salzuflen, Germany.
Shiyang PanThe Department of Laboratory Medicine of the First Affiliated Hospital of Nanjing Medical University, China.
Jim HuggettNational Measurement Laboratory (NML) at LGC, Queens Rd, Teddington TW11 0LY, United Kingdom; School of Biosciences & Medicine, Faculty of Health & Medical Science, University of Surrey, Guildford GU2 7XH, United Kingdom.
Parviz Ahmad-NejadInstitute for Medical Laboratory Diagnostics, Helios University Hospital, Witten/Herdecke University, Germany. Electronic address: parviz.ahmad-nejad@helios-gesundheit.de.
IFCC Committee for Molecular Diagnostics C-MD
Jiangsu Province Hospital · CNNational Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the current COVID-19 pandemic, early and rapid diagnosis of potentially infected and contagious individuals enables containment of the disease through quarantine and contact tracing. The rapid global expansion of these diagnostic testing services raises questions concerning the current state of the art with regard to standardization of testing and quality assessment practices. The aim of this study was to provide a global overview of the test methods, laboratory procedures and quality assessment practices used for SARS-CoV-2 diagnostics.

methodsThe Molecular Diagnostics Committee of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC C-MD) initiated a survey among international laboratories performing molecular genetic detection of SARS-CoV-2. Questions on quality assurance, variant testing, sequencing and the transmission of findings were included in the survey.

resultsA total of 273 laboratories from 49 countries participated in the survey. The majority of the participating laboratories (92.2%) use reverse transcriptase polymerase chain reaction (RT-PCR). The majority of participating laboratories do not conduct testing to identify SARS CoV-2 variants. Participation in external quality assessment programs was reported by the majority of laboratories, however, 33.2% of the laboratories reported not participating in external quality assurance programmes.

conclusionsBased on the survey, molecular diagnostic methods for SARS-CoV-2 detection are clearly not standardized across different countries and laboratories. The survey found an array of responses in regard to sample preparation, collection, processing and reporting of results. This work suggests quality assurance is insufficiently performed by diagnostic laboratories conducting SARS-CoV-2 testing.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansPandemicsPathology, MolecularCOVID 19Molecular diagnosticsNAATRT-PCRSARS-CoV-2Survey

Identifiers

PMID35413298
PMCPMC8994408
OpenAlexW4223442523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.